Department of Hematology/Oncology, American University of Beirut Medical Center, P.O. Box 11-0236, Riad El Solh, Beirut 1107 2020, Lebanon.
Cancer Treat Rev. 2013 Oct;39(6):578-83. doi: 10.1016/j.ctrv.2012.12.004. Epub 2013 Jan 3.
Prostate cancer is a common disease amongst elderly men. Compared with younger patients, men over the age of 75 are more likely to present with advanced disease and have a greater risk of death from prostate cancer despite higher death rates from competing causes. Treatment options for advanced prostate cancer have improved considerably in the last two years. The immunotherapy sipuleucel-T, the cytotoxic cabazitaxel, the androgen biosynthesis inhibitor abiraterone acetate, the radioisotope radium-223 and the antiandrogen enzalutamide have all been shown to improve survival in randomized phase III studies for patients with metastatic castration-resistant prostate cancer. This review will focus on the clinical data regarding new treatment developments specifically applied to elderly patients with advanced prostate cancer.
前列腺癌是老年男性中常见的疾病。与年轻患者相比，75 岁以上的男性更有可能出现晚期疾病，并且尽管死于竞争原因的死亡率较高，但死于前列腺癌的风险更大。在过去两年中，晚期前列腺癌的治疗选择有了显著改善。免疫疗法 sipuleucel-T、细胞毒性药物 cabazitaxel、雄激素生物合成抑制剂 abiraterone acetate、放射性同位素镭-223 和抗雄激素恩杂鲁胺在转移性去势抵抗性前列腺癌的随机 III 期研究中均显示可提高生存率。这篇综述将重点关注专门应用于晚期前列腺癌老年患者的新治疗进展的临床数据。
